Does Cardiff Oncology Inc (CRDF) Stock Beat its Rivals in Biotechnology? – InvestorsObserver

Cardiff Oncology Inc (CRDF) is near the bottom in its industry group according to InvestorsObserver. CRDF gets an overall rating of 0. That means it scores higher than 0 percent of stocks. Cardiff Oncology Inc gets a 0 rank in the Biotechnology industry. Biotechnology is number 8 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 0 means the stock is more attractive than 0 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cardiff Oncology Inc (CRDF) stock has fallen -3.93% while the S&P 500 has risen 0.79% as of 1:28 PM on Wednesday, Jun 3. CRDF is lower by -$0.13 from the previous closing price of $3.31 on volume of 910,007 shares. Over the past year the S&P 500 is higher by 10.77% while CRDF has risen 7.07%. CRDF lost -$2.12 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read more:
Does Cardiff Oncology Inc (CRDF) Stock Beat its Rivals in Biotechnology? - InvestorsObserver